1. Home
  2. ATXS vs YSG Comparison

ATXS vs YSG Comparison

Compare ATXS & YSG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATXS
  • YSG
  • Stock Information
  • Founded
  • ATXS 2008
  • YSG 2016
  • Country
  • ATXS United States
  • YSG China
  • Employees
  • ATXS N/A
  • YSG N/A
  • Industry
  • ATXS Biotechnology: Pharmaceutical Preparations
  • YSG Package Goods/Cosmetics
  • Sector
  • ATXS Health Care
  • YSG Consumer Discretionary
  • Exchange
  • ATXS Nasdaq
  • YSG Nasdaq
  • Market Cap
  • ATXS 401.2M
  • YSG 362.5M
  • IPO Year
  • ATXS 2015
  • YSG 2020
  • Fundamental
  • Price
  • ATXS $4.04
  • YSG $3.98
  • Analyst Decision
  • ATXS Strong Buy
  • YSG
  • Analyst Count
  • ATXS 5
  • YSG 0
  • Target Price
  • ATXS $26.60
  • YSG N/A
  • AVG Volume (30 Days)
  • ATXS 369.7K
  • YSG 162.0K
  • Earning Date
  • ATXS 05-08-2025
  • YSG 05-21-2025
  • Dividend Yield
  • ATXS N/A
  • YSG N/A
  • EPS Growth
  • ATXS N/A
  • YSG N/A
  • EPS
  • ATXS N/A
  • YSG N/A
  • Revenue
  • ATXS N/A
  • YSG $464,908,550.00
  • Revenue This Year
  • ATXS N/A
  • YSG $16.55
  • Revenue Next Year
  • ATXS N/A
  • YSG $13.17
  • P/E Ratio
  • ATXS N/A
  • YSG N/A
  • Revenue Growth
  • ATXS N/A
  • YSG N/A
  • 52 Week Low
  • ATXS $3.56
  • YSG $2.60
  • 52 Week High
  • ATXS $12.92
  • YSG $6.13
  • Technical
  • Relative Strength Index (RSI)
  • ATXS 28.96
  • YSG 45.88
  • Support Level
  • ATXS $3.56
  • YSG $3.42
  • Resistance Level
  • ATXS $4.39
  • YSG $4.23
  • Average True Range (ATR)
  • ATXS 0.42
  • YSG 0.39
  • MACD
  • ATXS -0.04
  • YSG -0.08
  • Stochastic Oscillator
  • ATXS 22.61
  • YSG 32.00

About ATXS Astria Therapeutics Inc.

Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.

About YSG Yatsen Holding Limited

Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The Group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands.

Share on Social Networks: